Related Experiment Video
Updated: Nov 22, 2025
10:53
A Novel Application of Musculoskeletal Ultrasound Imaging
Published on: September 17, 2013
24.4K
Current Devices in TMVI and Their Limitations: Focus on Tendyne
1Oslo University Hospital, Oslo, Norway.
Frontiers in Cardiovascular Medicine
|January 11, 2021
Summary
Transcatheter mitral valve implantation (TMVI) offers a new option for mitral valve disease. The Tendyne™ valve shows promising results for mitral regurgitation and mitral annular calcification in early studies.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Device Technology
Background:
- Severe mitral regurgitation (MR) has high incidence and mortality, with limited treatment options.
- Transcatheter mitral valve repair (TMVR) devices like MitraClip exist, but transcatheter mitral valve implantation (TMVI) development lags behind transcatheter aortic valve implantation (TAVI).
- Significant challenges in TMVI include valve design, delivery systems, anchoring, and anatomical considerations like left ventricular outflow tract (LVOT) obstruction and paravalvular leak.
Purpose of the Study:
- To evaluate the feasibility and safety of transcatheter mitral valve implantation (TMVI) devices.
- To focus on the Tendyne™ valve, the only CE-approved TMVI device, assessing its performance in mitral regurgitation and mitral annular calcification.
- To present promising results from the early feasibility study (EFS) of the Tendyne™ valve.
Main Methods:
- Review of early feasibility studies (EFS) for transcatheter mitral valve implantation (TMVI) devices.
- Focus on the Tendyne™ valve, including its features (CE approval, size availability, repositionability, retrievability).
- Analysis of 1- and 2-year outcomes for the first 100 patients treated with the Tendyne™ valve.
Main Results:
- The Tendyne™ valve is the sole CE-approved transcatheter mitral valve implant, available in multiple sizes and offering repositionability.
- Early feasibility study results for the first 100 patients treated with the Tendyne™ valve at 1 and 2 years are promising.
- The Tendyne™ valve demonstrates initial feasibility for mitral regurgitation and promising results for implantation in cases of mitral annular calcification.
Conclusions:
- Transcatheter mitral valve implantation (TMVI) is expanding treatment options for mitral valve disease.
- The Tendyne™ valve shows promising safety and efficacy for mitral regurgitation and mitral annular calcification.
- Continued investigation and development of TMVI devices like Tendyne™ are crucial for managing complex mitral valve pathologies.
More Related Videos
Related Concept Videos
01:15Transmission Electron Microscopy
6.4K
In 1931, physicist Ernst Ruska—building on the idea that magnetic fields can direct an electron beam just as lenses can direct a beam of light in an optical microscope—developed the first prototype of the electron microscope. This development led to the development of the field of electron microscopy. In the transmission electron microscope (TEM), electrons are produced by a hot tungsten element and accelerated by a potential difference in an electron gun, which gives them up to 400...
6.4K
01:05Total Internal Reflection Fluorescence Microscopy
10.8K
Total internal reflection fluorescence microscopy or TIRF is an advanced microscopic technique used to visualize fluorophores in samples close to a solid surface with a higher refractive index, such as a glass coverslip. TIRF only allows fluorophores in proximity to the solid surface to be excited. When light from a medium with a lower refractive index (such as air) hits the glass coverslip at a critical angle, the light undergoes total internal reflection stead of passing through the glass.
10.8K